Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–359 of 359 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Zyban Clear all

Conditions: Major Depressive Disorder
Interventions: SSRI + placebo, Escitalopram + Bupropion SR, Venlafaxine XR + Mirtazapine; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 15
States / cities: Tuscaloosa, Alabama • Harbor City, California • Los Angeles, California + 12 more

Conditions: Tobacco Use Cessation, Tobacco Use Disorder
Interventions: Bupropion-SR, Placebo; Drug · Other
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 12 Years to 25 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Obesity, Overweight
Interventions: NB, CLI, Usual Care; Drug · Behavioral
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Denver, Colorado • St Louis, Missouri • Cary, North Carolina + 12 more

Conditions: Addiction, Opioid Use, Substance Use Disorders, Opioid Use Disorder
Interventions: Placebo, Auvelity; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Healthy Adult Male and Female Volunteers
Interventions: BICX104 naltrexone implantable pellet, Bupropion 150 mg XL, Naltrexone (depot); Drug
Lead sponsor: BioCorRx Pharmaceuticals Inc; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Binge-eating Disorder, Obesity
Interventions: NB medication (Naltrexone Bupropion combination), Behavioral Weight Loss (BWL) counseling, Placebo; Drug · Behavioral · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Advanced Solid Tumors, Metastatic Melanoma
Interventions: losartan, dextromethorphan, caffeine, omeprazole, midazolam, rosuvastatin, bupropion immediate release (IR), encorafenib, binimetinib, modafinil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 11
States / cities: Orange, California • Aurora, Colorado • Chicago, Illinois + 7 more

Conditions: Healthy Volunteers
Interventions: E2086; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Substance-Related Disorders
Interventions: midazolam(drug), digoxin (drug), Bupropion (drug), Methadone (drug); Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 40 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Nicotine Dependence
Interventions: Chantix, Zyban, Nicotine patches; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Charlotte, North Carolina • Durham, North Carolina • Raleigh, North Carolina + 1 more

Conditions: Tobacco Use Cessation, Smoking Cessation, Smoking, Tobacco Use Disorder
Interventions: AD + Integrated Tobacco Order Set; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 1,044 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Tobacco Use Disorder
Interventions: Bupropion and NRT; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Smoking Cessation
Interventions: Placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8,144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 77
States / cities: Mobile, Alabama • Phoenix, Arizona • Encino, California + 61 more

Conditions: Depression
Interventions: generic bupropion; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 25 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Nicotine Dependence, Nicotine Use Disorder
Interventions: Bupropion SR, Contingency Management, Placebo; Drug · Behavioral · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 12 Years to 21 Years
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Bipolar Disorder, Major Depression
Interventions: Selective Serotonin Reuptake Inhibitor (SSRI); Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 15 Years to 30 Years
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Depression, Suicide, Attempted
Interventions: fluoxetine, sertraline, citalopram, escitalopram, bupropion, mirtazapine, venlafaxine, lithium, Cognitive Behavioral Therapy; Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 12 Years to 18 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 6
States / cities: Baltimore, Maryland • New York, New York • Durham, North Carolina + 2 more

Conditions: Depression, Alcoholism, Suicidal Behavior
Interventions: fluoxetine, bupropion; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder, Partner Relational Disorder (V61.10)
Interventions: Weekly marital therapy, As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.; Behavioral · Drug
Lead sponsor: Duke University; Other
Eligibility: 60 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Participants
Interventions: Fluconazole, Bupropion, Itraconazole, BMS-986235; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: Major Depression, Dysthymia
Interventions: Escitalopram, Bupropion, Imipramine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Tobacco Use Disorder, Smoking Cessation
Interventions: Bupropion, Varenicline, Placebo, Smoking Cessation Counseling; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Depression, Depressive Disorder
Interventions: Brief Supportive Psychotherapy, CBASP, Medication Only; Behavioral · Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 8
States / cities: Tucson, Arizona • Palo Alto, California • Atlanta, Georgia + 4 more

Search by objective public record fields.

Combining Medications to Enhance Depression Outcomes

Effectiveness of Bupropion for Treating Nicotine Dependence in Young People

Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects

Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion

Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants

Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone

Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers

Implementation of HIT-Enhanced Tobacco Treatment for Hospitalized Smokers

Maintaining Abstinence in Chronic Cigarette Smokers - 1

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns

Combined Pharmaco/Behavior Therapy in Adolescent Smokers

Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI

Treatment of Adolescent Suicide Attempters (TASA)

Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism

Treatment of Mood and Marriage Study (TOMMS)

A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235

Treatment of Depression Following Multiple Brain Tests

Pharmacogenetics, Emotional Reactivity and Smoking

Research Evaluating the Value of Augmenting Medication With Psychotherapy